Using tirzepatide for type 2 diabetes: what the clinical evidence shows

What the SURPASS programme established about blood-sugar and weight outcomes

The clinical case for tirzepatide in type 2 diabetes rests on the SURPASS trial programme, a series of phase-3 studies in adults with type 2 diabetes across a range of treatment backgrounds. Across the programme, tirzepatide at 5mg, 10mg and 15mg produced reductions in HbA1c (the standard long-term marker of blood-glucose control) that compared favourably with other established diabetes medicines, including insulin glargine and semaglutide. Weight reduction was a consistent secondary finding. The NICE appraisal of tirzepatide (TA1026) noted the drug's dual GIP and GLP-1 agonism as a mechanistically distinct approach among currently available treatments.

It is worth being precise about what this means in practice. The SURPASS trials recruited people already living with type 2 diabetes, many of whom had tried other glucose-lowering medicines. The results are therefore specific to that population, and if you want a broader picture of how diabetes and tirzepatide interact across different clinical contexts, that page covers the treatment landscape in more detail. If you have type 2 diabetes and are considering tirzepatide, the starting point is your current treatment regimen and how well your blood sugar is controlled. The NHS tirzepatide medicines page sets out the licensed indications and standard precautions clearly.

Which people with type 2 diabetes are likely to be suitable, and what the prescriber weighs

Tirzepatide's type 2 diabetes licence covers adults whose blood-glucose control is inadequate on existing medication, or as an add-on to treatments such as metformin, SGLT2 inhibitors or insulin. But a licence criterion is a starting point, not a green light. A prescriber will look at your kidney function carefully, dose adjustments or caution may apply at lower eGFR values, and this is one reason the prescribing decision cannot be made on a questionnaire alone. They will also consider whether you have a history of pancreatitis, medullary thyroid carcinoma or multiple endocrine neoplasia type 2, all of which are contraindications.

People taking insulin alongside tirzepatide may need their insulin dose adjusted as glucose control improves, to reduce the risk of hypoglycaemia. This is not a reason to avoid tirzepatide, but it does mean close monitoring in the weeks after starting. Our page on how tirzepatide is used in diabetes explores the treatment context in more depth. If your diabetes is managed through a specialist service or an endocrinologist, it is worth telling them you are considering this medicine before starting, even via a private route.

Pregnancy, breastfeeding and actively trying to conceive are clear contraindications. Tirzepatide is not recommended in any of these situations, and anyone planning a pregnancy should discuss alternative glucose-lowering options with their GP or diabetes team well in advance of stopping contraception.

Side effects that matter specifically in diabetes (and when to seek help urgently

The gastrointestinal side-effect profile of tirzepatide) nausea, loose stools, vomiting, reduced appetite, is broadly the same whether someone is taking it for weight management or for diabetes. What differs in the diabetes context is the interaction with hypoglycaemia risk. GLP-1 and GIP receptor agonists do not themselves cause low blood sugar in people who are not on insulin or sulphonylureas, but combining them with those medicines does carry that risk. Symptoms to know: shakiness, sweating, confusion, rapid heartbeat.

The more urgent warning applies to pancreatitis. The MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as a known but infrequent risk with GLP-1 medicines. The signal to act is severe, persistent abdominal pain that spreads to the back, with or without vomiting, this needs same-day medical assessment, not a wait-and-see approach. Anyone who experiences this should stop the injection and call 111 or go to A&E. Suspected side effects from any medicine can be reported at the MHRA's Yellow Card scheme. On a practical note, keeping your pen stored correctly (in the fridge door between uses, away from the freezer compartment) matters because a pen that has been frozen or left in a hot car may not deliver the medicine reliably, even if it looks unchanged.

Private access through nume versus NHS diabetes prescribing

Tirzepatide is available on the NHS for type 2 diabetes through GP prescribing, subject to clinical criteria, but access is not uniform, and some practices have longer review timelines than others. The phased NHS rollout for weight management (separate from the diabetes indication) has also created some confusion about which licence applies to a given patient. For someone whose primary need is diabetes management, the GP remains the natural first port of call. People sometimes also ask about whether tirzepatide is appropriate for type 1 diabetes, and that page addresses the evidence and current clinical position on that question.

For those who want a faster route or are not yet meeting NHS criteria, a private prescription following a same-day clinical review is one option. At nume, a GPhC-registered Independent Prescriber, not an algorithm, reads your answers and medical history before any prescription is issued. You can read more about how we work and see the clinical team at our clinical team page. A fuller overview of the medicine itself is on our Mounjaro page. The cost context for private treatment is covered on our Mounjaro price comparison page. If you are considering tirzepatide alongside other diabetes treatments, the best outcome comes from ensuring your GP or specialist is informed, coordination between a private prescriber and your diabetes team is not just advisable, it is part of responsible prescribing. Speak to our prescribers to find out whether treatment is suitable for your specific situation.